These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34448414)

  • 41. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
    Smith TJ
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
    Hwang CJ; Nichols EE; Chon BH; Perry JD
    Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
    Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ
    J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
    Douglas RS
    Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Teprotumumab for thyroid-associated ophthalmopathy : OPTIC].
    Gärtner R; Nitschmann S
    Internist (Berl); 2020 Nov; 61(11):1208-1210. PubMed ID: 33025123
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
    Radulovich N; Van Brummen A; Chambers C; Zhang M
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Review of Novel Medical Treatments for Thyroid Eye Disease.
    Park JW; Yoon JS
    Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report.
    Ress BD; Gross EM
    Ann Otol Rhinol Laryngol; 2000 Apr; 109(4):435-7. PubMed ID: 10778901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease.
    Allen RC; Bradley EA; Fante RG; Lucarelli MJ
    Ophthalmology; 2021 Aug; 128(8):1125-1128. PubMed ID: 33823982
    [No Abstract]   [Full Text] [Related]  

  • 53. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease.
    Carter C; Marks M; Bundeff AW; Adewodu T; Alderman L
    Endocrine; 2024 Jan; 83(1):65-68. PubMed ID: 37725291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Teprotumumab-related Cutaneous Hypersensitivity Reactions.
    Dallalzadeh LO; Ting M; Topilow N; Robbins SL; Liu CY; Burkat CN; Korn BS; Kikkawa DO
    Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):e208-e210. PubMed ID: 37656913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
    Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
    Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
    Hwang CJ; Rebollo NP; Mechels KB; Perry JD
    Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metronidazole ototoxicity--report of two cases.
    Iqbal SM; Murthy JG; Banerjee PK; Vishwanathan KA
    J Laryngol Otol; 1999 Apr; 113(4):355-7. PubMed ID: 10474673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.